Glaukos Announces Participation in Upcoming Investor Conferences

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, announced its management's participation in key investor conferences. Highlights include a pre-recorded presentation at the Piper Sandler Annual Healthcare Conference available from November 22, 2021, along with one-on-one meetings on December 1, 2021. Additionally, Glaukos will feature at the Stephens Annual Investment Conference on November 29, 2021. Interested parties can access live and archived webcasts in the Investors section of the Glaukos website.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

• Piper Sandler Annual Healthcare Conference (a pre-recorded fireside chat presentation will be available for viewing beginning on Monday, November 22, 2021, at 10:00 a.m. EST; management will participate in one-on-one and group meetings on Wednesday, December 1, 2021)
• Stephens Annual Investment Conference on Monday, November 29, 2021, at 3:00 p.m. EST

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent^®, its first MIGS device, in the United States in 2012, its next-generation iStent inject^® device in the United States in 2018 and most recently, its iStent inject W device in the United States in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005263/en/

Chris Lewis

Sr. Director, Investor Relations, Corporate Strategy & Development

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

What events will Glaukos Corporation participate in November 2021?

Glaukos Corporation will participate in the Piper Sandler Annual Healthcare Conference on November 22, 2021, and the Stephens Annual Investment Conference on November 29, 2021.

When is the Piper Sandler Annual Healthcare Conference presentation scheduled?

The Piper Sandler Annual Healthcare Conference presentation will be available from November 22, 2021, at 10:00 a.m. EST.

When will Glaukos have one-on-one meetings during the Piper Sandler Conference?

Glaukos management will participate in one-on-one meetings on December 1, 2021, during the Piper Sandler Annual Healthcare Conference.

Where can I find the webcasts for Glaukos Corporation's investor events?

Webcasts for Glaukos Corporation's investor events will be available in the Investors section of their website at http://investors.glaukos.com.